Global Gene Therapy Viral Vector and Plasmid DNA Market Growth 2026-2032
The global Gene Therapy Viral Vector and Plasmid DNA market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Viral vector and plasmid DNA are tools to transfer genetic material into cells. Viral vectors are generally utilized as vectors for gene therapy. There are various types of vectors, such as lentivirus, adenovirus, adeno-associated virus (AAV), and others, which include herpes simplex virus and chimeric viral vectors.
United States market for Gene Therapy Viral Vector and Plasmid DNA is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Gene Therapy Viral Vector and Plasmid DNA is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Gene Therapy Viral Vector and Plasmid DNA is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Gene Therapy Viral Vector and Plasmid DNA players cover Lonza, Merck KGaA, Thermo Fisher Scientific, Charles River Laboratories, Catalent, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Gene Therapy Viral Vector and Plasmid DNA Industry Forecast” looks at past sales and reviews total world Gene Therapy Viral Vector and Plasmid DNA sales in 2025, providing a comprehensive analysis by region and market sector of projected Gene Therapy Viral Vector and Plasmid DNA sales for 2026 through 2032. With Gene Therapy Viral Vector and Plasmid DNA sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gene Therapy Viral Vector and Plasmid DNA industry.
This Insight Report provides a comprehensive analysis of the global Gene Therapy Viral Vector and Plasmid DNA landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Gene Therapy Viral Vector and Plasmid DNA portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gene Therapy Viral Vector and Plasmid DNA market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gene Therapy Viral Vector and Plasmid DNA and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gene Therapy Viral Vector and Plasmid DNA.
This report presents a comprehensive overview, market shares, and growth opportunities of Gene Therapy Viral Vector and Plasmid DNA market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Viral vector and plasmid DNA are tools to transfer genetic material into cells. Viral vectors are generally utilized as vectors for gene therapy. There are various types of vectors, such as lentivirus, adenovirus, adeno-associated virus (AAV), and others, which include herpes simplex virus and chimeric viral vectors.
United States market for Gene Therapy Viral Vector and Plasmid DNA is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Gene Therapy Viral Vector and Plasmid DNA is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Gene Therapy Viral Vector and Plasmid DNA is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Gene Therapy Viral Vector and Plasmid DNA players cover Lonza, Merck KGaA, Thermo Fisher Scientific, Charles River Laboratories, Catalent, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Gene Therapy Viral Vector and Plasmid DNA Industry Forecast” looks at past sales and reviews total world Gene Therapy Viral Vector and Plasmid DNA sales in 2025, providing a comprehensive analysis by region and market sector of projected Gene Therapy Viral Vector and Plasmid DNA sales for 2026 through 2032. With Gene Therapy Viral Vector and Plasmid DNA sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gene Therapy Viral Vector and Plasmid DNA industry.
This Insight Report provides a comprehensive analysis of the global Gene Therapy Viral Vector and Plasmid DNA landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Gene Therapy Viral Vector and Plasmid DNA portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gene Therapy Viral Vector and Plasmid DNA market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gene Therapy Viral Vector and Plasmid DNA and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gene Therapy Viral Vector and Plasmid DNA.
This report presents a comprehensive overview, market shares, and growth opportunities of Gene Therapy Viral Vector and Plasmid DNA market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Viral Vectors
- Plasmid DNA
- Cell and Gene Therapy
- Vaccine Development
- Research
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Lonza
- Merck KGaA
- Thermo Fisher Scientific
- Charles River Laboratories
- Catalent
- WuXi AppTec
- FUJIFILM
- GenScript Biotech
- Takara Bio
- Oxford Biomedica
- Novartis
- Precision Biosciences
- Bluebird Bio
- Sartorius AG
- Danaher
- SIRON Biotech
- VGXI
- Waisman Biomanufacturing
- Kaneka Eurogentec
- PlasmidFactory
- ATUM
- Addgene
- Cell and Gene Therapy Catapult
- Batavia biosciences
- Altogen Biosystems
- What is the 10-year outlook for the global Gene Therapy Viral Vector and Plasmid DNA market?
- What factors are driving Gene Therapy Viral Vector and Plasmid DNA market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Gene Therapy Viral Vector and Plasmid DNA market opportunities vary by end market size?
- How does Gene Therapy Viral Vector and Plasmid DNA break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Gene Therapy Viral Vector and Plasmid DNA Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Gene Therapy Viral Vector and Plasmid DNA by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Gene Therapy Viral Vector and Plasmid DNA by Country/Region, 2021, 2025 & 2032
2.2 Gene Therapy Viral Vector and Plasmid DNA Segment by Type
2.2.1 Viral Vectors
2.2.2 Plasmid DNA
2.2.3 Gene Therapy Viral Vector and Plasmid DNA Sales by Type
2.2.3.1 Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Type (2021-2026)
2.2.3.2 Global Gene Therapy Viral Vector and Plasmid DNA Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Gene Therapy Viral Vector and Plasmid DNA Sale Price by Type (2021-2026)
2.3 Gene Therapy Viral Vector and Plasmid DNA Segment by Application
2.3.1 Cell and Gene Therapy
2.3.2 Vaccine Development
2.3.3 Research
2.3.4 Gene Therapy Viral Vector and Plasmid DNA Sales by Application
2.3.4.1 Global Gene Therapy Viral Vector and Plasmid DNA Sale Market Share by Application (2021-2026)
2.3.4.2 Global Gene Therapy Viral Vector and Plasmid DNA Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Gene Therapy Viral Vector and Plasmid DNA Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Gene Therapy Viral Vector and Plasmid DNA Breakdown Data by Company
3.1.1 Global Gene Therapy Viral Vector and Plasmid DNA Annual Sales by Company (2021-2026)
3.1.2 Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Company (2021-2026)
3.2 Global Gene Therapy Viral Vector and Plasmid DNA Annual Revenue by Company (2021-2026)
3.2.1 Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Company (2021-2026)
3.2.2 Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Company (2021-2026)
3.3 Global Gene Therapy Viral Vector and Plasmid DNA Sale Price by Company
3.4 Key Manufacturers Gene Therapy Viral Vector and Plasmid DNA Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Gene Therapy Viral Vector and Plasmid DNA Product Location Distribution
3.4.2 Players Gene Therapy Viral Vector and Plasmid DNA Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR GENE THERAPY VIRAL VECTOR AND PLASMID DNA BY GEOGRAPHIC REGION
4.1 World Historic Gene Therapy Viral Vector and Plasmid DNA Market Size by Geographic Region (2021-2026)
4.1.1 Global Gene Therapy Viral Vector and Plasmid DNA Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Gene Therapy Viral Vector and Plasmid DNA Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Gene Therapy Viral Vector and Plasmid DNA Market Size by Country/Region (2021-2026)
4.2.1 Global Gene Therapy Viral Vector and Plasmid DNA Annual Sales by Country/Region (2021-2026)
4.2.2 Global Gene Therapy Viral Vector and Plasmid DNA Annual Revenue by Country/Region (2021-2026)
4.3 Americas Gene Therapy Viral Vector and Plasmid DNA Sales Growth
4.4 APAC Gene Therapy Viral Vector and Plasmid DNA Sales Growth
4.5 Europe Gene Therapy Viral Vector and Plasmid DNA Sales Growth
4.6 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Growth
5 AMERICAS
5.1 Americas Gene Therapy Viral Vector and Plasmid DNA Sales by Country
5.1.1 Americas Gene Therapy Viral Vector and Plasmid DNA Sales by Country (2021-2026)
5.1.2 Americas Gene Therapy Viral Vector and Plasmid DNA Revenue by Country (2021-2026)
5.2 Americas Gene Therapy Viral Vector and Plasmid DNA Sales by Type (2021-2026)
5.3 Americas Gene Therapy Viral Vector and Plasmid DNA Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Gene Therapy Viral Vector and Plasmid DNA Sales by Region
6.1.1 APAC Gene Therapy Viral Vector and Plasmid DNA Sales by Region (2021-2026)
6.1.2 APAC Gene Therapy Viral Vector and Plasmid DNA Revenue by Region (2021-2026)
6.2 APAC Gene Therapy Viral Vector and Plasmid DNA Sales by Type (2021-2026)
6.3 APAC Gene Therapy Viral Vector and Plasmid DNA Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Gene Therapy Viral Vector and Plasmid DNA by Country
7.1.1 Europe Gene Therapy Viral Vector and Plasmid DNA Sales by Country (2021-2026)
7.1.2 Europe Gene Therapy Viral Vector and Plasmid DNA Revenue by Country (2021-2026)
7.2 Europe Gene Therapy Viral Vector and Plasmid DNA Sales by Type (2021-2026)
7.3 Europe Gene Therapy Viral Vector and Plasmid DNA Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA by Country
8.1.1 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales by Country (2021-2026)
8.1.2 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Revenue by Country (2021-2026)
8.2 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales by Type (2021-2026)
8.3 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Gene Therapy Viral Vector and Plasmid DNA
10.3 Manufacturing Process Analysis of Gene Therapy Viral Vector and Plasmid DNA
10.4 Industry Chain Structure of Gene Therapy Viral Vector and Plasmid DNA
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Gene Therapy Viral Vector and Plasmid DNA Distributors
11.3 Gene Therapy Viral Vector and Plasmid DNA Customer
12 WORLD FORECAST REVIEW FOR GENE THERAPY VIRAL VECTOR AND PLASMID DNA BY GEOGRAPHIC REGION
12.1 Global Gene Therapy Viral Vector and Plasmid DNA Market Size Forecast by Region
12.1.1 Global Gene Therapy Viral Vector and Plasmid DNA Forecast by Region (2027-2032)
12.1.2 Global Gene Therapy Viral Vector and Plasmid DNA Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Gene Therapy Viral Vector and Plasmid DNA Forecast by Type (2027-2032)
12.7 Global Gene Therapy Viral Vector and Plasmid DNA Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Lonza
13.1.1 Lonza Company Information
13.1.2 Lonza Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.1.3 Lonza Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Lonza Main Business Overview
13.1.5 Lonza Latest Developments
13.2 Merck KGaA
13.2.1 Merck KGaA Company Information
13.2.2 Merck KGaA Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.2.3 Merck KGaA Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Merck KGaA Main Business Overview
13.2.5 Merck KGaA Latest Developments
13.3 Thermo Fisher Scientific
13.3.1 Thermo Fisher Scientific Company Information
13.3.2 Thermo Fisher Scientific Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.3.3 Thermo Fisher Scientific Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Thermo Fisher Scientific Main Business Overview
13.3.5 Thermo Fisher Scientific Latest Developments
13.4 Charles River Laboratories
13.4.1 Charles River Laboratories Company Information
13.4.2 Charles River Laboratories Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.4.3 Charles River Laboratories Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Charles River Laboratories Main Business Overview
13.4.5 Charles River Laboratories Latest Developments
13.5 Catalent
13.5.1 Catalent Company Information
13.5.2 Catalent Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.5.3 Catalent Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Catalent Main Business Overview
13.5.5 Catalent Latest Developments
13.6 WuXi AppTec
13.6.1 WuXi AppTec Company Information
13.6.2 WuXi AppTec Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.6.3 WuXi AppTec Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 WuXi AppTec Main Business Overview
13.6.5 WuXi AppTec Latest Developments
13.7 FUJIFILM
13.7.1 FUJIFILM Company Information
13.7.2 FUJIFILM Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.7.3 FUJIFILM Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 FUJIFILM Main Business Overview
13.7.5 FUJIFILM Latest Developments
13.8 GenScript Biotech
13.8.1 GenScript Biotech Company Information
13.8.2 GenScript Biotech Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.8.3 GenScript Biotech Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 GenScript Biotech Main Business Overview
13.8.5 GenScript Biotech Latest Developments
13.9 Takara Bio
13.9.1 Takara Bio Company Information
13.9.2 Takara Bio Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.9.3 Takara Bio Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Takara Bio Main Business Overview
13.9.5 Takara Bio Latest Developments
13.10 Oxford Biomedica
13.10.1 Oxford Biomedica Company Information
13.10.2 Oxford Biomedica Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.10.3 Oxford Biomedica Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Oxford Biomedica Main Business Overview
13.10.5 Oxford Biomedica Latest Developments
13.11 Novartis
13.11.1 Novartis Company Information
13.11.2 Novartis Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.11.3 Novartis Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Novartis Main Business Overview
13.11.5 Novartis Latest Developments
13.12 Precision Biosciences
13.12.1 Precision Biosciences Company Information
13.12.2 Precision Biosciences Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.12.3 Precision Biosciences Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Precision Biosciences Main Business Overview
13.12.5 Precision Biosciences Latest Developments
13.13 Bluebird Bio
13.13.1 Bluebird Bio Company Information
13.13.2 Bluebird Bio Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.13.3 Bluebird Bio Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Bluebird Bio Main Business Overview
13.13.5 Bluebird Bio Latest Developments
13.14 Sartorius AG
13.14.1 Sartorius AG Company Information
13.14.2 Sartorius AG Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.14.3 Sartorius AG Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Sartorius AG Main Business Overview
13.14.5 Sartorius AG Latest Developments
13.15 Danaher
13.15.1 Danaher Company Information
13.15.2 Danaher Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.15.3 Danaher Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Danaher Main Business Overview
13.15.5 Danaher Latest Developments
13.16 SIRON Biotech
13.16.1 SIRON Biotech Company Information
13.16.2 SIRON Biotech Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.16.3 SIRON Biotech Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 SIRON Biotech Main Business Overview
13.16.5 SIRON Biotech Latest Developments
13.17 VGXI
13.17.1 VGXI Company Information
13.17.2 VGXI Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.17.3 VGXI Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 VGXI Main Business Overview
13.17.5 VGXI Latest Developments
13.18 Waisman Biomanufacturing
13.18.1 Waisman Biomanufacturing Company Information
13.18.2 Waisman Biomanufacturing Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.18.3 Waisman Biomanufacturing Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Waisman Biomanufacturing Main Business Overview
13.18.5 Waisman Biomanufacturing Latest Developments
13.19 Kaneka Eurogentec
13.19.1 Kaneka Eurogentec Company Information
13.19.2 Kaneka Eurogentec Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.19.3 Kaneka Eurogentec Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Kaneka Eurogentec Main Business Overview
13.19.5 Kaneka Eurogentec Latest Developments
13.20 PlasmidFactory
13.20.1 PlasmidFactory Company Information
13.20.2 PlasmidFactory Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.20.3 PlasmidFactory Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 PlasmidFactory Main Business Overview
13.20.5 PlasmidFactory Latest Developments
13.21 ATUM
13.21.1 ATUM Company Information
13.21.2 ATUM Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.21.3 ATUM Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.21.4 ATUM Main Business Overview
13.21.5 ATUM Latest Developments
13.22 Addgene
13.22.1 Addgene Company Information
13.22.2 Addgene Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.22.3 Addgene Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.22.4 Addgene Main Business Overview
13.22.5 Addgene Latest Developments
13.23 Cell and Gene Therapy Catapult
13.23.1 Cell and Gene Therapy Catapult Company Information
13.23.2 Cell and Gene Therapy Catapult Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.23.3 Cell and Gene Therapy Catapult Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.23.4 Cell and Gene Therapy Catapult Main Business Overview
13.23.5 Cell and Gene Therapy Catapult Latest Developments
13.24 Batavia biosciences
13.24.1 Batavia biosciences Company Information
13.24.2 Batavia biosciences Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.24.3 Batavia biosciences Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.24.4 Batavia biosciences Main Business Overview
13.24.5 Batavia biosciences Latest Developments
13.25 Altogen Biosystems
13.25.1 Altogen Biosystems Company Information
13.25.2 Altogen Biosystems Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.25.3 Altogen Biosystems Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.25.4 Altogen Biosystems Main Business Overview
13.25.5 Altogen Biosystems Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Gene Therapy Viral Vector and Plasmid DNA Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Gene Therapy Viral Vector and Plasmid DNA by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Gene Therapy Viral Vector and Plasmid DNA by Country/Region, 2021, 2025 & 2032
2.2 Gene Therapy Viral Vector and Plasmid DNA Segment by Type
2.2.1 Viral Vectors
2.2.2 Plasmid DNA
2.2.3 Gene Therapy Viral Vector and Plasmid DNA Sales by Type
2.2.3.1 Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Type (2021-2026)
2.2.3.2 Global Gene Therapy Viral Vector and Plasmid DNA Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Gene Therapy Viral Vector and Plasmid DNA Sale Price by Type (2021-2026)
2.3 Gene Therapy Viral Vector and Plasmid DNA Segment by Application
2.3.1 Cell and Gene Therapy
2.3.2 Vaccine Development
2.3.3 Research
2.3.4 Gene Therapy Viral Vector and Plasmid DNA Sales by Application
2.3.4.1 Global Gene Therapy Viral Vector and Plasmid DNA Sale Market Share by Application (2021-2026)
2.3.4.2 Global Gene Therapy Viral Vector and Plasmid DNA Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Gene Therapy Viral Vector and Plasmid DNA Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Gene Therapy Viral Vector and Plasmid DNA Breakdown Data by Company
3.1.1 Global Gene Therapy Viral Vector and Plasmid DNA Annual Sales by Company (2021-2026)
3.1.2 Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Company (2021-2026)
3.2 Global Gene Therapy Viral Vector and Plasmid DNA Annual Revenue by Company (2021-2026)
3.2.1 Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Company (2021-2026)
3.2.2 Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Company (2021-2026)
3.3 Global Gene Therapy Viral Vector and Plasmid DNA Sale Price by Company
3.4 Key Manufacturers Gene Therapy Viral Vector and Plasmid DNA Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Gene Therapy Viral Vector and Plasmid DNA Product Location Distribution
3.4.2 Players Gene Therapy Viral Vector and Plasmid DNA Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR GENE THERAPY VIRAL VECTOR AND PLASMID DNA BY GEOGRAPHIC REGION
4.1 World Historic Gene Therapy Viral Vector and Plasmid DNA Market Size by Geographic Region (2021-2026)
4.1.1 Global Gene Therapy Viral Vector and Plasmid DNA Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Gene Therapy Viral Vector and Plasmid DNA Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Gene Therapy Viral Vector and Plasmid DNA Market Size by Country/Region (2021-2026)
4.2.1 Global Gene Therapy Viral Vector and Plasmid DNA Annual Sales by Country/Region (2021-2026)
4.2.2 Global Gene Therapy Viral Vector and Plasmid DNA Annual Revenue by Country/Region (2021-2026)
4.3 Americas Gene Therapy Viral Vector and Plasmid DNA Sales Growth
4.4 APAC Gene Therapy Viral Vector and Plasmid DNA Sales Growth
4.5 Europe Gene Therapy Viral Vector and Plasmid DNA Sales Growth
4.6 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Growth
5 AMERICAS
5.1 Americas Gene Therapy Viral Vector and Plasmid DNA Sales by Country
5.1.1 Americas Gene Therapy Viral Vector and Plasmid DNA Sales by Country (2021-2026)
5.1.2 Americas Gene Therapy Viral Vector and Plasmid DNA Revenue by Country (2021-2026)
5.2 Americas Gene Therapy Viral Vector and Plasmid DNA Sales by Type (2021-2026)
5.3 Americas Gene Therapy Viral Vector and Plasmid DNA Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Gene Therapy Viral Vector and Plasmid DNA Sales by Region
6.1.1 APAC Gene Therapy Viral Vector and Plasmid DNA Sales by Region (2021-2026)
6.1.2 APAC Gene Therapy Viral Vector and Plasmid DNA Revenue by Region (2021-2026)
6.2 APAC Gene Therapy Viral Vector and Plasmid DNA Sales by Type (2021-2026)
6.3 APAC Gene Therapy Viral Vector and Plasmid DNA Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Gene Therapy Viral Vector and Plasmid DNA by Country
7.1.1 Europe Gene Therapy Viral Vector and Plasmid DNA Sales by Country (2021-2026)
7.1.2 Europe Gene Therapy Viral Vector and Plasmid DNA Revenue by Country (2021-2026)
7.2 Europe Gene Therapy Viral Vector and Plasmid DNA Sales by Type (2021-2026)
7.3 Europe Gene Therapy Viral Vector and Plasmid DNA Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA by Country
8.1.1 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales by Country (2021-2026)
8.1.2 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Revenue by Country (2021-2026)
8.2 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales by Type (2021-2026)
8.3 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Gene Therapy Viral Vector and Plasmid DNA
10.3 Manufacturing Process Analysis of Gene Therapy Viral Vector and Plasmid DNA
10.4 Industry Chain Structure of Gene Therapy Viral Vector and Plasmid DNA
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Gene Therapy Viral Vector and Plasmid DNA Distributors
11.3 Gene Therapy Viral Vector and Plasmid DNA Customer
12 WORLD FORECAST REVIEW FOR GENE THERAPY VIRAL VECTOR AND PLASMID DNA BY GEOGRAPHIC REGION
12.1 Global Gene Therapy Viral Vector and Plasmid DNA Market Size Forecast by Region
12.1.1 Global Gene Therapy Viral Vector and Plasmid DNA Forecast by Region (2027-2032)
12.1.2 Global Gene Therapy Viral Vector and Plasmid DNA Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Gene Therapy Viral Vector and Plasmid DNA Forecast by Type (2027-2032)
12.7 Global Gene Therapy Viral Vector and Plasmid DNA Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Lonza
13.1.1 Lonza Company Information
13.1.2 Lonza Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.1.3 Lonza Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Lonza Main Business Overview
13.1.5 Lonza Latest Developments
13.2 Merck KGaA
13.2.1 Merck KGaA Company Information
13.2.2 Merck KGaA Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.2.3 Merck KGaA Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Merck KGaA Main Business Overview
13.2.5 Merck KGaA Latest Developments
13.3 Thermo Fisher Scientific
13.3.1 Thermo Fisher Scientific Company Information
13.3.2 Thermo Fisher Scientific Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.3.3 Thermo Fisher Scientific Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Thermo Fisher Scientific Main Business Overview
13.3.5 Thermo Fisher Scientific Latest Developments
13.4 Charles River Laboratories
13.4.1 Charles River Laboratories Company Information
13.4.2 Charles River Laboratories Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.4.3 Charles River Laboratories Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Charles River Laboratories Main Business Overview
13.4.5 Charles River Laboratories Latest Developments
13.5 Catalent
13.5.1 Catalent Company Information
13.5.2 Catalent Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.5.3 Catalent Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Catalent Main Business Overview
13.5.5 Catalent Latest Developments
13.6 WuXi AppTec
13.6.1 WuXi AppTec Company Information
13.6.2 WuXi AppTec Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.6.3 WuXi AppTec Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 WuXi AppTec Main Business Overview
13.6.5 WuXi AppTec Latest Developments
13.7 FUJIFILM
13.7.1 FUJIFILM Company Information
13.7.2 FUJIFILM Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.7.3 FUJIFILM Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 FUJIFILM Main Business Overview
13.7.5 FUJIFILM Latest Developments
13.8 GenScript Biotech
13.8.1 GenScript Biotech Company Information
13.8.2 GenScript Biotech Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.8.3 GenScript Biotech Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 GenScript Biotech Main Business Overview
13.8.5 GenScript Biotech Latest Developments
13.9 Takara Bio
13.9.1 Takara Bio Company Information
13.9.2 Takara Bio Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.9.3 Takara Bio Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Takara Bio Main Business Overview
13.9.5 Takara Bio Latest Developments
13.10 Oxford Biomedica
13.10.1 Oxford Biomedica Company Information
13.10.2 Oxford Biomedica Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.10.3 Oxford Biomedica Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Oxford Biomedica Main Business Overview
13.10.5 Oxford Biomedica Latest Developments
13.11 Novartis
13.11.1 Novartis Company Information
13.11.2 Novartis Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.11.3 Novartis Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Novartis Main Business Overview
13.11.5 Novartis Latest Developments
13.12 Precision Biosciences
13.12.1 Precision Biosciences Company Information
13.12.2 Precision Biosciences Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.12.3 Precision Biosciences Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Precision Biosciences Main Business Overview
13.12.5 Precision Biosciences Latest Developments
13.13 Bluebird Bio
13.13.1 Bluebird Bio Company Information
13.13.2 Bluebird Bio Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.13.3 Bluebird Bio Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Bluebird Bio Main Business Overview
13.13.5 Bluebird Bio Latest Developments
13.14 Sartorius AG
13.14.1 Sartorius AG Company Information
13.14.2 Sartorius AG Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.14.3 Sartorius AG Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Sartorius AG Main Business Overview
13.14.5 Sartorius AG Latest Developments
13.15 Danaher
13.15.1 Danaher Company Information
13.15.2 Danaher Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.15.3 Danaher Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Danaher Main Business Overview
13.15.5 Danaher Latest Developments
13.16 SIRON Biotech
13.16.1 SIRON Biotech Company Information
13.16.2 SIRON Biotech Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.16.3 SIRON Biotech Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 SIRON Biotech Main Business Overview
13.16.5 SIRON Biotech Latest Developments
13.17 VGXI
13.17.1 VGXI Company Information
13.17.2 VGXI Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.17.3 VGXI Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 VGXI Main Business Overview
13.17.5 VGXI Latest Developments
13.18 Waisman Biomanufacturing
13.18.1 Waisman Biomanufacturing Company Information
13.18.2 Waisman Biomanufacturing Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.18.3 Waisman Biomanufacturing Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Waisman Biomanufacturing Main Business Overview
13.18.5 Waisman Biomanufacturing Latest Developments
13.19 Kaneka Eurogentec
13.19.1 Kaneka Eurogentec Company Information
13.19.2 Kaneka Eurogentec Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.19.3 Kaneka Eurogentec Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Kaneka Eurogentec Main Business Overview
13.19.5 Kaneka Eurogentec Latest Developments
13.20 PlasmidFactory
13.20.1 PlasmidFactory Company Information
13.20.2 PlasmidFactory Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.20.3 PlasmidFactory Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 PlasmidFactory Main Business Overview
13.20.5 PlasmidFactory Latest Developments
13.21 ATUM
13.21.1 ATUM Company Information
13.21.2 ATUM Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.21.3 ATUM Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.21.4 ATUM Main Business Overview
13.21.5 ATUM Latest Developments
13.22 Addgene
13.22.1 Addgene Company Information
13.22.2 Addgene Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.22.3 Addgene Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.22.4 Addgene Main Business Overview
13.22.5 Addgene Latest Developments
13.23 Cell and Gene Therapy Catapult
13.23.1 Cell and Gene Therapy Catapult Company Information
13.23.2 Cell and Gene Therapy Catapult Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.23.3 Cell and Gene Therapy Catapult Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.23.4 Cell and Gene Therapy Catapult Main Business Overview
13.23.5 Cell and Gene Therapy Catapult Latest Developments
13.24 Batavia biosciences
13.24.1 Batavia biosciences Company Information
13.24.2 Batavia biosciences Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.24.3 Batavia biosciences Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.24.4 Batavia biosciences Main Business Overview
13.24.5 Batavia biosciences Latest Developments
13.25 Altogen Biosystems
13.25.1 Altogen Biosystems Company Information
13.25.2 Altogen Biosystems Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
13.25.3 Altogen Biosystems Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2021-2026)
13.25.4 Altogen Biosystems Main Business Overview
13.25.5 Altogen Biosystems Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Gene Therapy Viral Vector and Plasmid DNA Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Gene Therapy Viral Vector and Plasmid DNA Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Viral Vectors
Table 4. Major Players of Plasmid DNA
Table 5. Global Gene Therapy Viral Vector and Plasmid DNA Sales by Type (2021-2026) & (K Units)
Table 6. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Type (2021-2026)
Table 7. Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Type (2021-2026) & ($ million)
Table 8. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Type (2021-2026)
Table 9. Global Gene Therapy Viral Vector and Plasmid DNA Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Gene Therapy Viral Vector and Plasmid DNA Sale by Application (2021-2026) & (K Units)
Table 11. Global Gene Therapy Viral Vector and Plasmid DNA Sale Market Share by Application (2021-2026)
Table 12. Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Application (2021-2026) & ($ million)
Table 13. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Application (2021-2026)
Table 14. Global Gene Therapy Viral Vector and Plasmid DNA Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Gene Therapy Viral Vector and Plasmid DNA Sales by Company (2021-2026) & (K Units)
Table 16. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Company (2021-2026)
Table 17. Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Company (2021-2026)
Table 19. Global Gene Therapy Viral Vector and Plasmid DNA Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Gene Therapy Viral Vector and Plasmid DNA Producing Area Distribution and Sales Area
Table 21. Players Gene Therapy Viral Vector and Plasmid DNA Products Offered
Table 22. Gene Therapy Viral Vector and Plasmid DNA Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Gene Therapy Viral Vector and Plasmid DNA Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share Geographic Region (2021-2026)
Table 27. Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Gene Therapy Viral Vector and Plasmid DNA Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Country/Region (2021-2026)
Table 31. Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Gene Therapy Viral Vector and Plasmid DNA Sales by Country (2021-2026) & (K Units)
Table 34. Americas Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Country (2021-2026)
Table 35. Americas Gene Therapy Viral Vector and Plasmid DNA Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Gene Therapy Viral Vector and Plasmid DNA Sales by Type (2021-2026) & (K Units)
Table 37. Americas Gene Therapy Viral Vector and Plasmid DNA Sales by Application (2021-2026) & (K Units)
Table 38. APAC Gene Therapy Viral Vector and Plasmid DNA Sales by Region (2021-2026) & (K Units)
Table 39. APAC Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Region (2021-2026)
Table 40. APAC Gene Therapy Viral Vector and Plasmid DNA Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Gene Therapy Viral Vector and Plasmid DNA Sales by Type (2021-2026) & (K Units)
Table 42. APAC Gene Therapy Viral Vector and Plasmid DNA Sales by Application (2021-2026) & (K Units)
Table 43. Europe Gene Therapy Viral Vector and Plasmid DNA Sales by Country (2021-2026) & (K Units)
Table 44. Europe Gene Therapy Viral Vector and Plasmid DNA Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Gene Therapy Viral Vector and Plasmid DNA Sales by Type (2021-2026) & (K Units)
Table 46. Europe Gene Therapy Viral Vector and Plasmid DNA Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Gene Therapy Viral Vector and Plasmid DNA
Table 52. Key Market Challenges & Risks of Gene Therapy Viral Vector and Plasmid DNA
Table 53. Key Industry Trends of Gene Therapy Viral Vector and Plasmid DNA
Table 54. Gene Therapy Viral Vector and Plasmid DNA Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Gene Therapy Viral Vector and Plasmid DNA Distributors List
Table 57. Gene Therapy Viral Vector and Plasmid DNA Customer List
Table 58. Global Gene Therapy Viral Vector and Plasmid DNA Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Gene Therapy Viral Vector and Plasmid DNA Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Gene Therapy Viral Vector and Plasmid DNA Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Gene Therapy Viral Vector and Plasmid DNA Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Gene Therapy Viral Vector and Plasmid DNA Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Gene Therapy Viral Vector and Plasmid DNA Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Gene Therapy Viral Vector and Plasmid DNA Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Gene Therapy Viral Vector and Plasmid DNA Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Gene Therapy Viral Vector and Plasmid DNA Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Lonza Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 73. Lonza Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 74. Lonza Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Lonza Main Business
Table 76. Lonza Latest Developments
Table 77. Merck KGaA Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 78. Merck KGaA Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 79. Merck KGaA Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Merck KGaA Main Business
Table 81. Merck KGaA Latest Developments
Table 82. Thermo Fisher Scientific Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 83. Thermo Fisher Scientific Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 84. Thermo Fisher Scientific Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Thermo Fisher Scientific Main Business
Table 86. Thermo Fisher Scientific Latest Developments
Table 87. Charles River Laboratories Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 88. Charles River Laboratories Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 89. Charles River Laboratories Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Charles River Laboratories Main Business
Table 91. Charles River Laboratories Latest Developments
Table 92. Catalent Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 93. Catalent Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 94. Catalent Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Catalent Main Business
Table 96. Catalent Latest Developments
Table 97. WuXi AppTec Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 98. WuXi AppTec Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 99. WuXi AppTec Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. WuXi AppTec Main Business
Table 101. WuXi AppTec Latest Developments
Table 102. FUJIFILM Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 103. FUJIFILM Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 104. FUJIFILM Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. FUJIFILM Main Business
Table 106. FUJIFILM Latest Developments
Table 107. GenScript Biotech Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 108. GenScript Biotech Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 109. GenScript Biotech Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. GenScript Biotech Main Business
Table 111. GenScript Biotech Latest Developments
Table 112. Takara Bio Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 113. Takara Bio Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 114. Takara Bio Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Takara Bio Main Business
Table 116. Takara Bio Latest Developments
Table 117. Oxford Biomedica Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 118. Oxford Biomedica Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 119. Oxford Biomedica Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. Oxford Biomedica Main Business
Table 121. Oxford Biomedica Latest Developments
Table 122. Novartis Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 123. Novartis Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 124. Novartis Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 125. Novartis Main Business
Table 126. Novartis Latest Developments
Table 127. Precision Biosciences Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 128. Precision Biosciences Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 129. Precision Biosciences Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 130. Precision Biosciences Main Business
Table 131. Precision Biosciences Latest Developments
Table 132. Bluebird Bio Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 133. Bluebird Bio Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 134. Bluebird Bio Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 135. Bluebird Bio Main Business
Table 136. Bluebird Bio Latest Developments
Table 137. Sartorius AG Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 138. Sartorius AG Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 139. Sartorius AG Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 140. Sartorius AG Main Business
Table 141. Sartorius AG Latest Developments
Table 142. Danaher Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 143. Danaher Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 144. Danaher Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 145. Danaher Main Business
Table 146. Danaher Latest Developments
Table 147. SIRON Biotech Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 148. SIRON Biotech Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 149. SIRON Biotech Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 150. SIRON Biotech Main Business
Table 151. SIRON Biotech Latest Developments
Table 152. VGXI Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 153. VGXI Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 154. VGXI Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 155. VGXI Main Business
Table 156. VGXI Latest Developments
Table 157. Waisman Biomanufacturing Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 158. Waisman Biomanufacturing Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 159. Waisman Biomanufacturing Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 160. Waisman Biomanufacturing Main Business
Table 161. Waisman Biomanufacturing Latest Developments
Table 162. Kaneka Eurogentec Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 163. Kaneka Eurogentec Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 164. Kaneka Eurogentec Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 165. Kaneka Eurogentec Main Business
Table 166. Kaneka Eurogentec Latest Developments
Table 167. PlasmidFactory Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 168. PlasmidFactory Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 169. PlasmidFactory Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 170. PlasmidFactory Main Business
Table 171. PlasmidFactory Latest Developments
Table 172. ATUM Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 173. ATUM Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 174. ATUM Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 175. ATUM Main Business
Table 176. ATUM Latest Developments
Table 177. Addgene Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 178. Addgene Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 179. Addgene Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 180. Addgene Main Business
Table 181. Addgene Latest Developments
Table 182. Cell and Gene Therapy Catapult Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 183. Cell and Gene Therapy Catapult Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 184. Cell and Gene Therapy Catapult Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 185. Cell and Gene Therapy Catapult Main Business
Table 186. Cell and Gene Therapy Catapult Latest Developments
Table 187. Batavia biosciences Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 188. Batavia biosciences Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 189. Batavia biosciences Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 190. Batavia biosciences Main Business
Table 191. Batavia biosciences Latest Developments
Table 192. Altogen Biosystems Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 193. Altogen Biosystems Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 194. Altogen Biosystems Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 195. Altogen Biosystems Main Business
Table 196. Altogen Biosystems Latest Developments
Table 1. Gene Therapy Viral Vector and Plasmid DNA Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Gene Therapy Viral Vector and Plasmid DNA Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Viral Vectors
Table 4. Major Players of Plasmid DNA
Table 5. Global Gene Therapy Viral Vector and Plasmid DNA Sales by Type (2021-2026) & (K Units)
Table 6. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Type (2021-2026)
Table 7. Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Type (2021-2026) & ($ million)
Table 8. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Type (2021-2026)
Table 9. Global Gene Therapy Viral Vector and Plasmid DNA Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Gene Therapy Viral Vector and Plasmid DNA Sale by Application (2021-2026) & (K Units)
Table 11. Global Gene Therapy Viral Vector and Plasmid DNA Sale Market Share by Application (2021-2026)
Table 12. Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Application (2021-2026) & ($ million)
Table 13. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Application (2021-2026)
Table 14. Global Gene Therapy Viral Vector and Plasmid DNA Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Gene Therapy Viral Vector and Plasmid DNA Sales by Company (2021-2026) & (K Units)
Table 16. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Company (2021-2026)
Table 17. Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Company (2021-2026)
Table 19. Global Gene Therapy Viral Vector and Plasmid DNA Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Gene Therapy Viral Vector and Plasmid DNA Producing Area Distribution and Sales Area
Table 21. Players Gene Therapy Viral Vector and Plasmid DNA Products Offered
Table 22. Gene Therapy Viral Vector and Plasmid DNA Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Gene Therapy Viral Vector and Plasmid DNA Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share Geographic Region (2021-2026)
Table 27. Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Gene Therapy Viral Vector and Plasmid DNA Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Country/Region (2021-2026)
Table 31. Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Gene Therapy Viral Vector and Plasmid DNA Sales by Country (2021-2026) & (K Units)
Table 34. Americas Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Country (2021-2026)
Table 35. Americas Gene Therapy Viral Vector and Plasmid DNA Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Gene Therapy Viral Vector and Plasmid DNA Sales by Type (2021-2026) & (K Units)
Table 37. Americas Gene Therapy Viral Vector and Plasmid DNA Sales by Application (2021-2026) & (K Units)
Table 38. APAC Gene Therapy Viral Vector and Plasmid DNA Sales by Region (2021-2026) & (K Units)
Table 39. APAC Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Region (2021-2026)
Table 40. APAC Gene Therapy Viral Vector and Plasmid DNA Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Gene Therapy Viral Vector and Plasmid DNA Sales by Type (2021-2026) & (K Units)
Table 42. APAC Gene Therapy Viral Vector and Plasmid DNA Sales by Application (2021-2026) & (K Units)
Table 43. Europe Gene Therapy Viral Vector and Plasmid DNA Sales by Country (2021-2026) & (K Units)
Table 44. Europe Gene Therapy Viral Vector and Plasmid DNA Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Gene Therapy Viral Vector and Plasmid DNA Sales by Type (2021-2026) & (K Units)
Table 46. Europe Gene Therapy Viral Vector and Plasmid DNA Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Gene Therapy Viral Vector and Plasmid DNA
Table 52. Key Market Challenges & Risks of Gene Therapy Viral Vector and Plasmid DNA
Table 53. Key Industry Trends of Gene Therapy Viral Vector and Plasmid DNA
Table 54. Gene Therapy Viral Vector and Plasmid DNA Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Gene Therapy Viral Vector and Plasmid DNA Distributors List
Table 57. Gene Therapy Viral Vector and Plasmid DNA Customer List
Table 58. Global Gene Therapy Viral Vector and Plasmid DNA Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Gene Therapy Viral Vector and Plasmid DNA Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Gene Therapy Viral Vector and Plasmid DNA Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Gene Therapy Viral Vector and Plasmid DNA Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Gene Therapy Viral Vector and Plasmid DNA Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Gene Therapy Viral Vector and Plasmid DNA Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Gene Therapy Viral Vector and Plasmid DNA Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Gene Therapy Viral Vector and Plasmid DNA Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Gene Therapy Viral Vector and Plasmid DNA Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Lonza Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 73. Lonza Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 74. Lonza Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Lonza Main Business
Table 76. Lonza Latest Developments
Table 77. Merck KGaA Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 78. Merck KGaA Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 79. Merck KGaA Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Merck KGaA Main Business
Table 81. Merck KGaA Latest Developments
Table 82. Thermo Fisher Scientific Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 83. Thermo Fisher Scientific Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 84. Thermo Fisher Scientific Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Thermo Fisher Scientific Main Business
Table 86. Thermo Fisher Scientific Latest Developments
Table 87. Charles River Laboratories Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 88. Charles River Laboratories Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 89. Charles River Laboratories Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Charles River Laboratories Main Business
Table 91. Charles River Laboratories Latest Developments
Table 92. Catalent Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 93. Catalent Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 94. Catalent Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Catalent Main Business
Table 96. Catalent Latest Developments
Table 97. WuXi AppTec Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 98. WuXi AppTec Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 99. WuXi AppTec Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. WuXi AppTec Main Business
Table 101. WuXi AppTec Latest Developments
Table 102. FUJIFILM Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 103. FUJIFILM Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 104. FUJIFILM Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. FUJIFILM Main Business
Table 106. FUJIFILM Latest Developments
Table 107. GenScript Biotech Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 108. GenScript Biotech Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 109. GenScript Biotech Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. GenScript Biotech Main Business
Table 111. GenScript Biotech Latest Developments
Table 112. Takara Bio Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 113. Takara Bio Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 114. Takara Bio Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Takara Bio Main Business
Table 116. Takara Bio Latest Developments
Table 117. Oxford Biomedica Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 118. Oxford Biomedica Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 119. Oxford Biomedica Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. Oxford Biomedica Main Business
Table 121. Oxford Biomedica Latest Developments
Table 122. Novartis Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 123. Novartis Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 124. Novartis Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 125. Novartis Main Business
Table 126. Novartis Latest Developments
Table 127. Precision Biosciences Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 128. Precision Biosciences Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 129. Precision Biosciences Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 130. Precision Biosciences Main Business
Table 131. Precision Biosciences Latest Developments
Table 132. Bluebird Bio Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 133. Bluebird Bio Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 134. Bluebird Bio Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 135. Bluebird Bio Main Business
Table 136. Bluebird Bio Latest Developments
Table 137. Sartorius AG Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 138. Sartorius AG Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 139. Sartorius AG Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 140. Sartorius AG Main Business
Table 141. Sartorius AG Latest Developments
Table 142. Danaher Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 143. Danaher Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 144. Danaher Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 145. Danaher Main Business
Table 146. Danaher Latest Developments
Table 147. SIRON Biotech Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 148. SIRON Biotech Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 149. SIRON Biotech Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 150. SIRON Biotech Main Business
Table 151. SIRON Biotech Latest Developments
Table 152. VGXI Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 153. VGXI Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 154. VGXI Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 155. VGXI Main Business
Table 156. VGXI Latest Developments
Table 157. Waisman Biomanufacturing Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 158. Waisman Biomanufacturing Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 159. Waisman Biomanufacturing Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 160. Waisman Biomanufacturing Main Business
Table 161. Waisman Biomanufacturing Latest Developments
Table 162. Kaneka Eurogentec Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 163. Kaneka Eurogentec Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 164. Kaneka Eurogentec Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 165. Kaneka Eurogentec Main Business
Table 166. Kaneka Eurogentec Latest Developments
Table 167. PlasmidFactory Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 168. PlasmidFactory Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 169. PlasmidFactory Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 170. PlasmidFactory Main Business
Table 171. PlasmidFactory Latest Developments
Table 172. ATUM Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 173. ATUM Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 174. ATUM Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 175. ATUM Main Business
Table 176. ATUM Latest Developments
Table 177. Addgene Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 178. Addgene Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 179. Addgene Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 180. Addgene Main Business
Table 181. Addgene Latest Developments
Table 182. Cell and Gene Therapy Catapult Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 183. Cell and Gene Therapy Catapult Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 184. Cell and Gene Therapy Catapult Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 185. Cell and Gene Therapy Catapult Main Business
Table 186. Cell and Gene Therapy Catapult Latest Developments
Table 187. Batavia biosciences Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 188. Batavia biosciences Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 189. Batavia biosciences Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 190. Batavia biosciences Main Business
Table 191. Batavia biosciences Latest Developments
Table 192. Altogen Biosystems Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
Table 193. Altogen Biosystems Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
Table 194. Altogen Biosystems Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 195. Altogen Biosystems Main Business
Table 196. Altogen Biosystems Latest Developments
LIST OF FIGURES
Figure 1. Picture of Gene Therapy Viral Vector and Plasmid DNA
Figure 2. Gene Therapy Viral Vector and Plasmid DNA Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Gene Therapy Viral Vector and Plasmid DNA Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Gene Therapy Viral Vector and Plasmid DNA Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Country/Region (2025)
Figure 10. Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Viral Vectors
Figure 12. Product Picture of Plasmid DNA
Figure 13. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Type in 2026
Figure 14. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Type (2021-2026)
Figure 15. Gene Therapy Viral Vector and Plasmid DNA Consumed in Cell and Gene Therapy
Figure 16. Global Gene Therapy Viral Vector and Plasmid DNA Market: Cell and Gene Therapy (2021-2026) & (K Units)
Figure 17. Gene Therapy Viral Vector and Plasmid DNA Consumed in Vaccine Development
Figure 18. Global Gene Therapy Viral Vector and Plasmid DNA Market: Vaccine Development (2021-2026) & (K Units)
Figure 19. Gene Therapy Viral Vector and Plasmid DNA Consumed in Research
Figure 20. Global Gene Therapy Viral Vector and Plasmid DNA Market: Research (2021-2026) & (K Units)
Figure 21. Global Gene Therapy Viral Vector and Plasmid DNA Sale Market Share by Application (2025)
Figure 22. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Application in 2026
Figure 23. Gene Therapy Viral Vector and Plasmid DNA Sales by Company in 2026 (K Units)
Figure 24. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Company in 2026
Figure 25. Gene Therapy Viral Vector and Plasmid DNA Revenue by Company in 2026 ($ millions)
Figure 26. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Company in 2026
Figure 27. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Geographic Region (2021-2026)
Figure 28. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Geographic Region in 2026
Figure 29. Americas Gene Therapy Viral Vector and Plasmid DNA Sales 2021-2026 (K Units)
Figure 30. Americas Gene Therapy Viral Vector and Plasmid DNA Revenue 2021-2026 ($ millions)
Figure 31. APAC Gene Therapy Viral Vector and Plasmid DNA Sales 2021-2026 (K Units)
Figure 32. APAC Gene Therapy Viral Vector and Plasmid DNA Revenue 2021-2026 ($ millions)
Figure 33. Europe Gene Therapy Viral Vector and Plasmid DNA Sales 2021-2026 (K Units)
Figure 34. Europe Gene Therapy Viral Vector and Plasmid DNA Revenue 2021-2026 ($ millions)
Figure 35. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales 2021-2026 (K Units)
Figure 36. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Revenue 2021-2026 ($ millions)
Figure 37. Americas Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Country in 2026
Figure 38. Americas Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Country (2021-2026)
Figure 39. Americas Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Type (2021-2026)
Figure 40. Americas Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Application (2021-2026)
Figure 41. United States Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 42. Canada Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 43. Mexico Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 44. Brazil Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 45. APAC Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Region in 2026
Figure 46. APAC Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Region (2021-2026)
Figure 47. APAC Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Type (2021-2026)
Figure 48. APAC Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Application (2021-2026)
Figure 49. China Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 50. Japan Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 51. South Korea Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 52. Southeast Asia Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 53. India Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 54. Australia Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 55. China Taiwan Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 56. Europe Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Country in 2026
Figure 57. Europe Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Country (2021-2026)
Figure 58. Europe Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Type (2021-2026)
Figure 59. Europe Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Application (2021-2026)
Figure 60. Germany Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 61. France Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 62. UK Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 63. Italy Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 64. Russia Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 65. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Country (2021-2026)
Figure 66. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Type (2021-2026)
Figure 67. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Application (2021-2026)
Figure 68. Egypt Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 69. South Africa Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 70. Israel Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 71. Turkey Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 72. GCC Countries Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Gene Therapy Viral Vector and Plasmid DNA in 2026
Figure 74. Manufacturing Process Analysis of Gene Therapy Viral Vector and Plasmid DNA
Figure 75. Industry Chain Structure of Gene Therapy Viral Vector and Plasmid DNA
Figure 76. Channels of Distribution
Figure 77. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Forecast by Region (2027-2032)
Figure 78. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share Forecast by Region (2027-2032)
Figure 79. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share Forecast by Type (2027-2032)
Figure 80. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share Forecast by Type (2027-2032)
Figure 81. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share Forecast by Application (2027-2032)
Figure 82. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Gene Therapy Viral Vector and Plasmid DNA
Figure 2. Gene Therapy Viral Vector and Plasmid DNA Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Gene Therapy Viral Vector and Plasmid DNA Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Gene Therapy Viral Vector and Plasmid DNA Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Country/Region (2025)
Figure 10. Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Viral Vectors
Figure 12. Product Picture of Plasmid DNA
Figure 13. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Type in 2026
Figure 14. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Type (2021-2026)
Figure 15. Gene Therapy Viral Vector and Plasmid DNA Consumed in Cell and Gene Therapy
Figure 16. Global Gene Therapy Viral Vector and Plasmid DNA Market: Cell and Gene Therapy (2021-2026) & (K Units)
Figure 17. Gene Therapy Viral Vector and Plasmid DNA Consumed in Vaccine Development
Figure 18. Global Gene Therapy Viral Vector and Plasmid DNA Market: Vaccine Development (2021-2026) & (K Units)
Figure 19. Gene Therapy Viral Vector and Plasmid DNA Consumed in Research
Figure 20. Global Gene Therapy Viral Vector and Plasmid DNA Market: Research (2021-2026) & (K Units)
Figure 21. Global Gene Therapy Viral Vector and Plasmid DNA Sale Market Share by Application (2025)
Figure 22. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Application in 2026
Figure 23. Gene Therapy Viral Vector and Plasmid DNA Sales by Company in 2026 (K Units)
Figure 24. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Company in 2026
Figure 25. Gene Therapy Viral Vector and Plasmid DNA Revenue by Company in 2026 ($ millions)
Figure 26. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Company in 2026
Figure 27. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Geographic Region (2021-2026)
Figure 28. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Geographic Region in 2026
Figure 29. Americas Gene Therapy Viral Vector and Plasmid DNA Sales 2021-2026 (K Units)
Figure 30. Americas Gene Therapy Viral Vector and Plasmid DNA Revenue 2021-2026 ($ millions)
Figure 31. APAC Gene Therapy Viral Vector and Plasmid DNA Sales 2021-2026 (K Units)
Figure 32. APAC Gene Therapy Viral Vector and Plasmid DNA Revenue 2021-2026 ($ millions)
Figure 33. Europe Gene Therapy Viral Vector and Plasmid DNA Sales 2021-2026 (K Units)
Figure 34. Europe Gene Therapy Viral Vector and Plasmid DNA Revenue 2021-2026 ($ millions)
Figure 35. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales 2021-2026 (K Units)
Figure 36. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Revenue 2021-2026 ($ millions)
Figure 37. Americas Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Country in 2026
Figure 38. Americas Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Country (2021-2026)
Figure 39. Americas Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Type (2021-2026)
Figure 40. Americas Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Application (2021-2026)
Figure 41. United States Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 42. Canada Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 43. Mexico Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 44. Brazil Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 45. APAC Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Region in 2026
Figure 46. APAC Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Region (2021-2026)
Figure 47. APAC Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Type (2021-2026)
Figure 48. APAC Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Application (2021-2026)
Figure 49. China Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 50. Japan Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 51. South Korea Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 52. Southeast Asia Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 53. India Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 54. Australia Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 55. China Taiwan Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 56. Europe Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Country in 2026
Figure 57. Europe Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Country (2021-2026)
Figure 58. Europe Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Type (2021-2026)
Figure 59. Europe Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Application (2021-2026)
Figure 60. Germany Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 61. France Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 62. UK Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 63. Italy Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 64. Russia Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 65. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Country (2021-2026)
Figure 66. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Type (2021-2026)
Figure 67. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Application (2021-2026)
Figure 68. Egypt Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 69. South Africa Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 70. Israel Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 71. Turkey Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 72. GCC Countries Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2021-2026 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Gene Therapy Viral Vector and Plasmid DNA in 2026
Figure 74. Manufacturing Process Analysis of Gene Therapy Viral Vector and Plasmid DNA
Figure 75. Industry Chain Structure of Gene Therapy Viral Vector and Plasmid DNA
Figure 76. Channels of Distribution
Figure 77. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Forecast by Region (2027-2032)
Figure 78. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share Forecast by Region (2027-2032)
Figure 79. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share Forecast by Type (2027-2032)
Figure 80. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share Forecast by Type (2027-2032)
Figure 81. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share Forecast by Application (2027-2032)
Figure 82. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share Forecast by Application (2027-2032)
